Opna Bio doses first subject in Phase I trial of treatment for multiple myeloma
Opna Bio has dosed the first subject in a Phase I trial of OPN-6602, an EP300/CBP bromodomain inhibitor for multiple myeloma. The open-label study aims to enroll up to 130 subjects to evaluate safety, tolerability, pharmacokinetics, and early anti-tumor activity. The trial includes a dose-escalation phase with 90 patients and a dose-expansion phase with 40 patients, expected to complete in H2 2026.
Highlighted Terms
Related News
Opna Bio has dosed the first subject in a Phase I trial of OPN-6602, an EP300/CBP bromodomain inhibitor for multiple myeloma. The open-label study aims to enroll up to 130 subjects to evaluate safety, tolerability, pharmacokinetics, and early anti-tumor activity. The trial includes a dose-escalation phase with 90 patients and a dose-expansion phase with 40 patients, expected to complete in H2 2026.